Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus NOXAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus NOXAFIL.
FOCINVEZ vs NOXAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Inhibits fungal cytochrome P450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
Posaconazole oral suspension: 200 mg (5 mL) three times daily with food. Oral delayed-release tablets: 300 mg twice daily on day 1, then 300 mg once daily thereafter with food. IV: 300 mg twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life is approximately 25-30 hours (range 20-66 hours) in healthy subjects; in patients with hepatic impairment or critical illness, half-life may be prolonged up to 40-50 hours; supports once-daily dosing in most patients.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Primarily hepatic metabolism (glucuronidation) with extensive enterohepatic recirculation; renal excretion accounts for <1% as unchanged drug; approximately 71% of a radiolabeled dose is eliminated in feces (as parent drug and metabolites) and 13% in urine (as metabolites).
Category C
Category C
Antifungal
Antifungal